Publications by authors named "Ina Hierlmeier"

Claim this Profile
A
Assessing the potential of bacterial signal peptides for radiopharmaceutical applications.
Zukaa Al Taleb, Ina Hierlmeier, Heiko Heilmann, Martin Jung, Mark Bartholomä

Sci Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiochemistry of cyclen-derived chelators comprising five-membered azaheterocyclic arms with Pb, Bi, and Ac.
Ina Hierlmeier, Parmissa Randhawa, Brooke L McNeil, Elisa Oliveri, Stephan Maus

Nucl Med Biol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiochemistry and Complex Formation of the Cyclen-Derived Chelator DOTI-Me with Mn, Cu, Zn, Ga, In, Tb, and Lu.
Ina Hierlmeier, Nadia Marino, Moritz-Valentin Schreck, Lukas Schneider, Stephan Maus

Inorg Chem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HNODThia: A Promising Chelator for the Development of Cu Radiopharmaceuticals.
Ina Hierlmeier, Amaury Guillou, Daniel F Earley, Anthony Linden, Jason P Holland

Inorg Chem· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me.
Moritz-Valentin Schreck, Caroline Burgard, Alexander Schmidtke, Ina Hierlmeier, Tobias Stemler

Mol Pharm· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioconjugated chelates based on (methylpyridinyl)tacn: synthesis, 64Cu labeling and in vitro evaluation for prostate cancer targeting.
Axia Marlin, Ina Hierlmeier, Amaury Guillou, Mark Bartholomä, Raphaël Tripier

Metallomics· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates.
Tobias Stemler, Caroline Hoffmann, Ina M Hierlmeier, Stephan Maus, Elmar Krause

ChemMedChem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value of Combined PET Imaging with [F]FDG and [Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [Lu]Lu-PSMA-617 RLT.
Fadi Khreish, Kalle Ribbat, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier

Cancers (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.
Florian Rosar, Jonas Krause, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier

Pharmaceutics· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [Lu]Lu-PSMA-617.
Sebastian Martin, Roswitha Tönnesmann, Ina Hierlmeier, Stephan Maus, Florian Rosar

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis